Abstract: The present disclosure relates to topical scalp care compositions that may be used as leave-on treatments and comprise one or more actives useful for treating symptoms of itch, redness, flaking, and dryness of the scalp. The present disclosure further relates to systems and methods of treating symptoms of itch, redness, flaking, and dryness of the scalp using such topical scalp care compositions.

Abstract: A topical skincare composition including a Centella asiatica extract including one or more triterpenes, wherein at least one of the one or more triterpenes is madecassic acid, an Avena (oat) extract, a ceramide and a dermatologically acceptable carrier. A method of treating symptoms of itch, redness, flaking, dryness, and/or roughness of the skin, scalp, and/or mucous membrane including the step of applying the topical skincare composition to at least a portion of a user's skin, scalp, and/or mucous membrane in need thereof.

Abstract: A topical skincare composition including a Centella asiatica extract including one or more triterpenes, wherein at least one of the one or more triterpenes is madecassic acid, an Avena (oat) extract, a ceramide and a dermatologically acceptable carrier. A method of treating symptoms of itch, redness, flaking, dryness, and/or roughness of the skin, scalp, and/or mucous membrane including the step of applying the topical skincare composition to at least a portion of a user's skin, scalp, and/or mucous membrane in need thereof.

Abstract: A topical skincare composition including a Centella asiatica extract including one or more triterpenes, wherein at least one of the one or more triterpenes is madecassic acid, an Avena (oat) extract, a ceramide and a dermatologically acceptable carrier. A method of treating symptoms of itch, redness, flaking, dryness, and/or roughness of the skin, scalp, and/or mucous membrane including the step of applying the topical skincare composition to at least a portion of a user's skin, scalp, and/or mucous membrane in need thereof.

Abstract: A method of improving the appearance of periorbital dyschromia by identifying a target portion of skin in the periorbital region of a person that exhibits periorbital dyschromia and applying a personal care composition to the target portion of skin during a treatment period. The personal care composition includes an effective amount of Type I active, an effective amount of a Type II active, and a dermatologically acceptable carrier. The treatment period is of sufficient length for at least one of the actives to improve the appearance of the periorbital dyschromia.

Abstract: A method and system for classifying different types of periorbital dyschromia is disclosed. The method includes providing at least one of a predetermined imaging characteristic and a biological characteristic for each of three different types of periorbital dyschromia, and then measuring the appropriate characteristic on a person exhibiting periorbital dyschromia. The type of periorbital dyschromia exhibited by a person can then be determined by comparing the measured value to the predetermined value and selecting the corresponding type of periorbital dyschromia.

Abstract: A method of improving the appearance of periorbital dyschromia by identifying a target portion of skin in the periorbital region of a person that exhibits periorbital dyschromia and applying a personal care composition to the target portion of skin. The personal care composition includes an effective amount of an extract of Cucurbita pepo and a dermatologically acceptable carrier. The personal care composition is applied for a sufficient amount of time for the extract of Cucurbita pepo to improve the appearance of the periorbital dyschromia.

Abstract: The present application is directed, generally, to an array of products and methods for treating periorbital dyschromia. More specifically, the present application discloses an array of products and methods for treating different types of periorbital dyschromia. The products and methods utilize extracts of Cucurbita pepo.

Abstract: A cosmetic composition for improving the appearance of Type II and/or Type III periorbital dyschromia. The composition includes an effective amount of an extract of Vicia faba and a dermatologically acceptable carrier. The composition may be disposed in a package that includes verbal and/or non-verbal indicia to communicate to a user that the composition is intended to treat a particular type of periorbital dyschromia.

Abstract: A method of improving the appearance of periorbital dyschromia by identifying a target portion of skin in the periorbital region of a person that exhibits periorbital dyschromia and applying a personal care composition to the target portion of skin. The personal care composition includes an effective amount of an extract of Vicia faba and a dermatologically acceptable carrier. The personal care composition is applied for a sufficient amount of time for the extract of Vicia faba to improve the appearance of the periorbital dyschromia.

Abstract: The application is directed, generally, to an array of products and methods for treating periorbital dyschromia. More specifically, the application discloses an array of products and methods for treating different types of periorbital dyschromia. The products and methods utilize extracts of Vicia faba.

Abstract: A method of improving the appearance of periorbital dyschromia by identifying a target portion of skin in the periorbital region of a person that exhibits periorbital dyschromia and applying a personal care composition to the target portion of skin during a treatment period. The personal care composition includes an effective amount of Type I active, an effective amount of a Type II active, and a dermatologically acceptable carrier. The treatment period is of sufficient length for at least one of the actives to improve the appearance of the periorbital dyschromia.

Abstract: A method of constructing a data architecture for use in identifying connections between perturbagens and genes associated with a type of periorbital dyschromia. The method includes providing a gene expression profile for a keratinocyte, fibroblast, melanocyte or melanoma cell, which has been exposed to at least one perturbagen, and comparing the gene expression profile to a control cell from the same cell line. Genes that are differentially expressed in response to the perturbagen are identified by comparing the gene expression profiles of the control cell and the test cell. An ordered list of identifiers representing the differentially expressed genes is created according to the differential expression of the genes. The ordered list is stored as an instance on a computer readable medium. The steps are then repeated to construct a data architecture of stored instances.